Nuvectis Pharma, Inc. (NVCT)

NASDAQ: NVCT · USD

$18.3

-0.18 (-1.0%)· Recorded snapshot

Market cap	594.9M
Net income (ttm)	-30.3M
EPS (ttm)	-$1.30
Shares out	32.6M
Volume	161,885
Beta	-0.24

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -30.3M
EPS (ttm): -$1.30
Market cap: 594.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-214.6

P25 n/aP50 n/aP75 n/a

ROIC-139

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NVCT indicators

Market & fundamental data

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001875558
Company name	Nuvectis Pharma, Inc.
Country	United States
Country code	US
CUSIP number	67080T108
Earnings date	2026-11-10
Earnings time	bmo
Employees	16
Employees change	3
Employees growth	23.08%
Enterprise value	$572.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2020
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2022-02-04
Is primary listing	Yes
Is SPAC	No
ISIN number	US67080T1088
Last 10-K release date	2026-02-11
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$594.9M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$18.26
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	NVCT
U.S. state	New Jersey
Website	https://www.nuvectis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-7.14%
FCF / EV yield	-3.41%
FCF yield	-3.28%
P/B ratio	54.2x
Price / tangible book value	65.4x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.9M
ROA	-73.07%
ROCE	-317.86%
ROE	-214.58%
ROE (5Y)	-269.3%
ROIC	-139.03%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-28.9M
EPS	$-1.30
FCF per share	$-0.60
Financing cash flow	$14.9M
Free cash flow	$-19.5M
Free cash flow minus SBC	$-26M
Net cash flow	$-4.6M
Net income	$-30.3M
Operating cash flow minus SBC	$-26M
Operating income	$-28.9M
Stock-based compensation	$6.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.34
Debt / equity	0
Long-term assets	$0
Long-term liabilities	$0
Net cash (debt)	$22.2M
Net cash / market cap	3.73%
Net cash growth	-17.29%
Net debt / equity	-2.44
Piotroski F-Score	1
Shareholders' equity	$9.1M
Tangible book value	$9.1M
Tangible book value per share	$0.34
Total assets	$22.4M
Total cash	$22.2M
Total debt	$0
Total liabilities	$13.3M
WACC	2.92%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$22.4M
Current liabilities	$13.3M
Current ratio	1.68
Net working capital	$-13.1M
Quick ratio	1.67
Working capital	$9.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-21.66%
Dividend yield	0%
Shareholder yield	-21.66%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$16.46
1D price change	-0.98%
1M price change	-9.4%
1M total return	-9.4%
1W price change	-11.5%
1W total return	-11.5%
1Y price change	179.7%
1Y return CAGR	179.89%
1Y total return	179.7%
20-day SMA	$19.77
200-day SMA	$14.51
3M price change	-6.24%
3M total return	-6.24%
3Y price change	117.06%
3Y return CAGR	29.47%
3Y total return	117.06%
50-day SMA	$21.64
50-day SMA vs 200-day SMA	50over200
52-week high	$29.28
52-week high date	2026-06-29
52-week low	$5.55
52-week low date	2025-11-07
6M price change	109.37%
6M total return	109.37%
All-time high	$29.28
All-time high date	2026-06-29
All-time low	$3.08
All-time low date	2022-02-04
Average true range (ATR)	$1.45
Average volume	173.3K
Beta (1Y)	-0.99
Beta (2Y)	1.27
Beta (5Y)	-0.24
Change from 52-week high	-37.63%
Change from 52-week low	229.01%
Change from all-time high	-37.42%
Change from all-time low	494.81%
Change from open	-1.3%
Day's gap	0.33%
Dollar volume	$3M
High price	$18.70
Low price	$18.00
Monthly RSI	64.77
Open price	$18.50
Position in 52-week range	37.14%
Premarket change	1.41%
Premarket close	$18.44
Premarket price	$18.70
Previous close	$18.44
Price vs 150-day SMA	11.27%
Price vs 20-day SMA	-7.33%
Price vs 200-day SMA	26.25%
Price vs 50-day SMA	-15.34%
Relative volume	0.95
Return from IPO open	361.52%
Return from IPO price	264.6%
RSI	40.2
Sharpe ratio	1.59
Sharpe ratio (3Y)	0.67
Sortino ratio	2.66
Sortino ratio (3Y)	1.1
Volume	161.9K
Weekly RSI	51.13
YTD price change	142.65%
YTD total return	142.65%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	21.2M
Float percentage	65.08%
Shares change (QoQ)	0.26%
Shares change (YoY)	21.66%
Shares held by insiders	34.92%
Shares held by institutions	33.84%
Shares outstanding	32.6M
Short % of float	11.89%
Short % of shares	7.74%
Short ratio	12.3 days

Deeper analysis on NVCT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NVCT report

Is a complete NVCT research report available?

No complete published report is available for Nuvectis Pharma, Inc. (NVCT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Nuvectis Pharma, Inc. (NVCT)

Price

Financial snapshot

Fair-value bridge

Latest news · NVCT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NVCT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NVCT

Frequently asked questions